Kezar Life Sciences
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
4000 Shoreline Ct Ste 300, South San Fra...Phone Number
(650) 822-5600Website
www.kezarlifesciences.comRevenue
-Stock Symbol
KZRIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
2
1
1
About Kezar Life Sciences
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Explore more
Kezar Life Sciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Kezar Life Sciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Kezar Life Sciences, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Kezar Life Sciences has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Click to see if Kezar Life Sciences had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Kezar Life Sciences has new funding data
Congratulate Masked Content for being promoted to Masked Content at Kezar Life Sciences
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Kezar Life Sciences is spiking on competitors!
Product Launch: Get notified when Kezar Life Sciences launches new products
Earning: See what the market has to say on Kezar Life Sciences recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Kezar Life Sciences
Compare insights from companies similar to Kezar Life Sciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Kezar Life Sciences is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Kezar Life Sciences is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Kezar Life Sciences.
Kezar Life Sciences Tech Stack
A closer look at the technologies used by Kezar Life Sciences
See more technologies
Most Recent Scoops
Person-Based
Stake & Stock Ownership, Finance, Financial Transactions
Person-Based
Stake & Stock Ownership, Finance
Person-Based
Compensation & Benefits, HR Operations
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Kezar Life Sciences News & Media
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Division of Hepatology and Nutrition of the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the completed PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a first-in-class selective immunoproteasome inhibitor, inKezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Chris Kirk, Chief Executive Officer and Co-founder, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 2:35 pm ET in New York, NY. A webcast of the panel discussion will be available on the “EvenKezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. “We shared exciting results this quarter from the PORTOLA trial, the first successful randomized study in treatment-refractory AIH,” said Chris Kirk, CEO and co-founderKezar Life Sciences, Inc. (KZR) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call (Transcript)
Kezar Life Sciences, Inc. (NASDAQ:KZR) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call March 25, 2025 8:00 AM ETCompany...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Kezar Life Sciences
Sign Up For FreeTo access detailed company insights
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b... Read More
